AFM
CKPT

Anson Funds Management’s Checkpoint Therapeutics CKPT Stock Holding History

Anson Funds Management’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-31,125
Closed -$535K – 69
2019
Q4 		$535K Buy
+31,125
New +$521K 0.62% 44

Other funds holding CKPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Anson Funds Management's CKPT Position: Q1 2020 in Review

Anson Funds Management sold out of Checkpoint Therapeutics (CKPT) in Q1 2020, closing a stake of 31,125 shares — an estimated $535K sold.

Anson Funds Management first reported a position in CKPT in Q4 2019 and held it in 1 quarter. The position peaked at $535K in Q4 2019. 41 funds tracked by Wall St. Rank hold CKPT as of Q1 2020.

  • Anson Funds Management reported no remaining Checkpoint Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Anson Funds Management sold 31,125 Checkpoint Therapeutics shares in Q1 2020, an estimated $535K.
  • Anson Funds Management first reported a position in Checkpoint Therapeutics in Q4 2019 and held it in 1 quarter.
  • Anson Funds Management's Checkpoint Therapeutics position peaked at $535K in Q4 2019.
  • 41 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2020.

Based on Anson Funds Management's 13F filing for Q1 2020, filed 15 May 2020.